Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers

Background: The innovative injection of interleukin 17 A (IL-17A) monoclonal antibody QX002N is being developed to treat active ankylosing spondylitis and plaque psoriasis in adults. Objective: This study investigated the pharmacokinetics (PKs), pharmacodynamics (PDs) safety, tolerability, and immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Min, Zhang, Hong, Li, Qianqian, Chen, Hong, Fang, Min, Yang, Lizhi, Ding, Yanhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931745/
https://www.ncbi.nlm.nih.gov/pubmed/35310892
http://dx.doi.org/10.3389/fphar.2021.794054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931745/
https://www.ncbi.nlm.nih.gov/pubmed/35310892
http://dx.doi.org/10.3389/fphar.2021.794054

Ejemplares similares